Literature DB >> 31251848

Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis.

Khodayar Goshtasbi1, Arash Abiri1, Mehdi Abouzari1, Ronald Sahyouni1, Beverly Y Wang2, Bobby A Tajudeen3, Frank P K Hsu4, Gilbert Cadena4, Edward C Kuan1.   

Abstract

BACKGROUND: Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, represents up to 3% of all sinonasal neoplasms. Hyams histologic grading is a promising tool in predicting metastases and establishing prognoses for this complex tumor.
METHODS: A systematic literature search was performed in the PubMed, Ovid MEDLINE, and Cochrane databases. ENB patients with Hyams I-II or III-IV were categorized as low-grade Hyams (LGH) or high-grade Hyams (HGH), respectively. Binary and continuous random-effects models were applied to calculate odds ratios (ORs) for the incidences of neck and distal metastases as well as for 5- and 10-year overall survival rates.
RESULTS: Of the 57 screened articles published from 1993 to 2018, 16 (525 patients) and 21 (563 patients) provided data for tumor metastases and overall survival rates, respectively. Neck metastasis was observed in 18.2% of HGH vs 7.9% of LGH patients. Distant metastasis was noted in 20.7% of HGH vs 8.9% of LGH patients. LGH patients had 5- and 10-year overall survival rates of 81.2% and 64.0%, respectively, as compared with 60.9% and 40.6%, respectively, for HGH patients. In comparing HGHs vs LGHs, the collective ORs for neck and distant metastases were 2.08 (95% confidence interval [CI], 1.09-3.99; p = 0.03) and 2.37 (95% CI, 1.07-5.26; p = 0.03), respectively. Moreover, in comparing LGHs vs HGHs, collective ORs for 5- and 10-year overall survival rates were 3.39 (95% CI, 2.09-5.49; p < 0.001) and 3.03 (95% CI, 1.82-5.06; p < 0.001), respectively.
CONCLUSION: HGH ENBs, compared with LGH ENBs, are more likely to metastasize to neck or distal targets and to have lower overall survival rates.
© 2019 ARS-AAOA, LLC.

Entities:  

Keywords:  esthesioneuroblastoma; meta-analysis; metastasis; olfactory neuroblastoma; survival

Mesh:

Year:  2019        PMID: 31251848      PMCID: PMC7276257          DOI: 10.1002/alr.22373

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  36 in total

Review 1.  Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.

Authors:  E A McElroy; J C Buckner; J E Lewis
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

3.  Survival outcomes for stage-matched endoscopic and open resection of olfactory neuroblastoma.

Authors:  Richard J Harvey; Sunny Nalavenkata; Raymond Sacks; Nithin D Adappa; James N Palmer; Michael T Purkey; Rodney J Schlosser; Carl Snyderman; Eric W Wang; Bradford A Woodworth; Robert Smee; Tom Havas; Richard Gallagher
Journal:  Head Neck       Date:  2017-09-25       Impact factor: 3.147

4.  Clinical features and the molecular biomarkers of olfactory neuroblastoma.

Authors:  Xiaolin Peng; Yao Liu; Xin Peng; Zhengming Wang; Zhe Zhang; Yuling Qiu; Meihua Jin; Ran Wang; Dexin Kong
Journal:  Pathol Res Pract       Date:  2018-06-10       Impact factor: 3.250

5.  Esthesioneuroblastoma: reflections of a 21-year experience.

Authors:  P A Levine; R Gallagher; R W Cantrell
Journal:  Laryngoscope       Date:  1999-10       Impact factor: 3.325

6.  Outcomes for olfactory neuroblastoma treated with induction chemotherapy.

Authors:  Shirley Y Su; Diana Bell; Renata Ferrarotto; Jack Phan; Dianna Roberts; Michael E Kupferman; Steven J Frank; C David Fuller; G Brandon Gunn; Merrill S Kies; Bonnie S Glisson; Ehab Y Hanna
Journal:  Head Neck       Date:  2017-05-31       Impact factor: 3.147

7.  The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck.

Authors:  Wen Jiang; Abdallah S R Mohamed; Clifton David Fuller; Betty Y S Kim; Chad Tang; G Brandon Gunn; Ehab Y Hanna; Steven J Frank; Shirley Y Su; Eduardo Diaz; Michael E Kupferman; Beth M Beadle; William H Morrison; Heath Skinner; Stephen Y Lai; Adel K El-Naggar; Franco DeMonte; David I Rosenthal; Adam S Garden; Jack Phan
Journal:  Pract Radiat Oncol       Date:  2015-11-10

8.  Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome.

Authors:  Gabriel G Malouf; Odile Casiraghi; Eric Deutsch; Joel Guigay; Stéphane Temam; Jean Bourhis
Journal:  Eur J Cancer       Date:  2013-01-10       Impact factor: 9.162

9.  Olfactory Neuroblastoma: Fate of the Neck--A Long-term Multicenter Retrospective Study.

Authors:  Sunny B Nalavenkata; Raymond Sacks; Nithin D Adappa; James N Palmer; Michael T Purkey; Michael D Feldman; Rodney J Schlosser; Carl H Snyderman; Eric W Wang; Bradford A Woodworth; Robert Smee; Thomas E Havas; Richard Gallagher; Richard J Harvey
Journal:  Otolaryngol Head Neck Surg       Date:  2015-12-15       Impact factor: 3.497

10.  Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database.

Authors:  Mary E Platek; Mihai Merzianu; Terry L Mashtare; Saurin R Popat; Nestor R Rigual; Graham W Warren; Anurag K Singh
Journal:  Radiat Oncol       Date:  2011-04-25       Impact factor: 3.481

View more
  8 in total

1.  Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.

Authors:  Matt Lechner; Yoko Takahashi; Mario Turri-Zanoni; Jacklyn Liu; Nicholas Counsell; Mario Hermsen; Raman Preet Kaur; Tianna Zhao; Murugappan Ramanathan; Volker H Schartinger; Oscar Emanuel; Sam Helman; Jordan Varghese; Jozsef Dudas; Herbert Riechelmann; Susanne Sprung; Johannes Haybaeck; David Howard; Nils Wolfgang Engel; Sarah Stewart; Laura Brooks; Jessica C Pickles; Thomas S Jacques; Tim R Fenton; Luke Williams; Francis M Vaz; Paul O'Flynn; Paul Stimpson; Simon Wang; S Alam Hannan; Samit Unadkat; Jonathan Hughes; Raghav Dwivedi; Cillian T Forde; Premjit Randhawa; Simon Gane; Jonathan Joseph; Peter J Andrews; Gary Royle; Alessandro Franchi; Roberta Maragliano; Simonetta Battocchio; Helen Bewicke-Copley; Christodoulos Pipinikas; Amy Webster; Chrissie Thirlwell; Debbie Ho; Andrew Teschendorff; Tianyu Zhu; Christopher D Steele; Nischalan Pillay; Bart Vanhaesebroeck; Ahmed Mohyeldin; Juan Fernandez-Miranda; Ki Wan Park; Quynh-Thu Le; Robert B West; Rami Saade; R Peter Manes; Sacit Bulent Omay; Eugenia M Vining; Benjamin L Judson; Wendell G Yarbrough; Maddalena Sansovini; Nicolini Silvia; Ilaria Grassi; Alberto Bongiovanni; David Capper; Ulrich Schüller; Selvam Thavaraj; Ann Sandison; Pavol Surda; Claire Hopkins; Marco Ferrari; Davide Mattavelli; Vittorio Rampinelli; Fabio Facchetti; Piero Nicolai; Paolo Bossi; Oswaldo A Henriquez; Kelly Magliocca; C Arturo Solares; Sarah K Wise; Jose L Llorente; Zara M Patel; Jayakar V Nayak; Peter H Hwang; Peter D Lacy; Robbie Woods; James P O'Neill; Amrita Jay; Dawn Carnell; Martin D Forster; Masaru Ishii; Nyall R London; Diana M Bell; Gary L Gallia; Paolo Castelnuovo; Stefano Severi; Valerie J Lund; Ehab Y Hanna
Journal:  Eur J Cancer       Date:  2021-12-31       Impact factor: 10.002

2.  Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience.

Authors:  Tongxin Liu; Quanquan Sun; Weifeng Qin; Xiaozhong Chen; Qiaoying Hu
Journal:  Cancer Manag Res       Date:  2020-09-10       Impact factor: 3.989

Review 3.  Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis.

Authors:  Huy Gia Vuong; Tam N M Ngo; Ian F Dunn
Journal:  J Neurooncol       Date:  2021-03-26       Impact factor: 4.130

Review 4.  Novel Biomarkers in Sinonasal Cancers: from Bench to Bedside.

Authors:  Matt Lechner; Jacklyn Liu; Valerie J Lund
Journal:  Curr Oncol Rep       Date:  2020-07-29       Impact factor: 5.075

5.  Short-Term Morbidity and Predictors of Adverse Events Following Esthesioneuroblastoma Surgery.

Authors:  Khodayar Goshtasbi; Jack L Birkenbeuel; Mehdi Abouzari; Brandon M Lehrich; Tyler M Yasaka; Arash Abiri; Ethan G Muhonen; Frank P K Hsu; Edward C Kuan
Journal:  Am J Rhinol Allergy       Date:  2020-10-29       Impact factor: 2.467

6.  A novel nomogram to predict the overall survival in esthesinoeroblastoma.

Authors:  Lijie Jiang; Tengjiao Lin; Yu Zhang; Wenxiang Gao; Jie Deng; Zhaofeng Xu; Xin Luo; Zhaoqi Huang; Fenghong Chen; Jianbo Shi; Yinyan Lai
Journal:  BMC Cancer       Date:  2020-10-14       Impact factor: 4.430

Review 7.  Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment.

Authors:  Mario Turri-Zanoni; Giacomo Gravante; Paolo Castelnuovo
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

8.  Olfactory Neuroblastoma: Re-Evaluating the Paradigm of Intracranial Extension and Cyst Formation.

Authors:  Rebecca A Dumont; Miguel Fernando Palma Diaz; William Hsu; Ali R Sepahdari
Journal:  Diagnostics (Basel)       Date:  2022-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.